The Association Between Genetic Polymorphisms of Transporter Genes and Prognosis of Platinum-Based Chemotherapy in Lung Cancer Patients.

Pharmacogenomics and Personalized Medicine Pub Date : 2022-09-14 eCollection Date: 2022-01-01 DOI:10.2147/PGPM.S375284

Jia He, Zhan Wang, Ting Zou, Ying Wang, Xiang-Ping Li, Juan Chen

{"title":"The Association Between Genetic Polymorphisms of Transporter Genes and Prognosis of Platinum-Based Chemotherapy in Lung Cancer Patients.","authors":"Jia He, Zhan Wang, Ting Zou, Ying Wang, Xiang-Ping Li, Juan Chen","doi":"10.2147/PGPM.S375284","DOIUrl":null,"url":null,"abstract":"Objective: Platinum-based chemotherapy is the first-line treatment of lung cancer. However, different individual and genetic variation effect therapy for lung cancer. The purpose of this study was to evaluate the association between transport genes genetic polymorphisms and the prognosis of platinum-based chemotherapy in lung cancer patients.Methods: A series of 593 patients with treatment of platinum-based chemotherapy were recruited for this study. A total of 21 single-nucleotide polymorphisms in nine transporter genes were selected to investigate their associations with platinum-based chemotherapy prognosis.Results: Patients with ABCG2 rs1448784 CC genotype had a significantly shorter PFS than CT or TT genotypes (Additive model: HR = 1.54, 95% CI = 1.02-2.35, P = 0.040). In stratification analysis, SLC22A2 rs316003, SLC2A1 rs4658 were related to PFS and AQP9 rs1867380, SLC2A1 rs3820589, SLC22A2 rs316003 indicated were related to OS of platinum-based chemotherapy prognosis.Conclusion: Genetic polymorphisms of rs1448784 in ABCG2 might be potential clinical marker for predicting the prognosis of lung cancer patients treated with platinum-based chemotherapy.","PeriodicalId":509088,"journal":{"name":"Pharmacogenomics and Personalized Medicine","volume":" ","pages":"817-825"},"PeriodicalIF":0.0000,"publicationDate":"2022-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b9/f2/pgpm-15-817.PMC9484078.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics and Personalized Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/PGPM.S375284","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Platinum-based chemotherapy is the first-line treatment of lung cancer. However, different individual and genetic variation effect therapy for lung cancer. The purpose of this study was to evaluate the association between transport genes genetic polymorphisms and the prognosis of platinum-based chemotherapy in lung cancer patients.

Methods: A series of 593 patients with treatment of platinum-based chemotherapy were recruited for this study. A total of 21 single-nucleotide polymorphisms in nine transporter genes were selected to investigate their associations with platinum-based chemotherapy prognosis.

Results: Patients with ABCG2 rs1448784 CC genotype had a significantly shorter PFS than CT or TT genotypes (Additive model: HR = 1.54, 95% CI = 1.02-2.35, P = 0.040). In stratification analysis, SLC22A2 rs316003, SLC2A1 rs4658 were related to PFS and AQP9 rs1867380, SLC2A1 rs3820589, SLC22A2 rs316003 indicated were related to OS of platinum-based chemotherapy prognosis.

Conclusion: Genetic polymorphisms of rs1448784 in ABCG2 might be potential clinical marker for predicting the prognosis of lung cancer patients treated with platinum-based chemotherapy.

Abstract Image

查看原文本刊更多论文

肺癌患者铂基化疗中转运蛋白基因遗传多态性与预后的关系

目的:铂类化疗是肺癌的一线治疗方案。然而，不同的个体和基因变异会影响肺癌的治疗。本研究的目的是评估转运基因遗传多态性与肺癌患者铂基化疗预后之间的关系。方法:593例接受铂类化疗的患者作为研究对象。我们选择了9个转运体基因中的21个单核苷酸多态性来研究它们与铂基化疗预后的关系。结果:ABCG2 rs1448784 CC基因型患者的PFS明显短于CT或TT基因型患者(加性模型:HR = 1.54, 95% CI = 1.02 ~ 2.35, P = 0.040)。在分层分析中，SLC22A2 rs316003、SLC2A1 rs4658与PFS相关，AQP9 rs1867380、SLC2A1 rs3820589、SLC22A2 rs316003提示与铂基化疗预后OS相关。结论:ABCG2中rs1448784基因多态性可能是预测肺癌患者铂类化疗预后的潜在临床指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacogenomics and Personalized Medicine

自引率

0.00%

发文量